Medical Care
Global Value-added Medicines (VAM) Development Service Market Research Report 2025
- Mar 11, 25
- ID: 18732
- Pages: 77
- Figures: 71
- Views: 18
The global market for Value-added Medicines (VAM) Development Service was valued at US$ 553 million in the year 2024 and is projected to reach a revised size of US$ 1059 million by 2031, growing at a CAGR of 10.5% during the forecast period.
Value-added Medicines Development Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
North American market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM) Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM) Development Service.
The Value-added Medicines (VAM) Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Altus Drug Development
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Galenicap
Sandoz AG
Adragos Pharma
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Pharmaceutical Companies
Biotech Companies
Hospitals and Medical Institutions
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Value-added Medicines (VAM) Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Value-added Medicines Development Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
North American market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM) Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM) Development Service.
The Value-added Medicines (VAM) Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Altus Drug Development
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Galenicap
Sandoz AG
Adragos Pharma
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Pharmaceutical Companies
Biotech Companies
Hospitals and Medical Institutions
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Value-added Medicines (VAM) Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Development Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Development Service Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Development Service Market Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service Market Drivers
2.3.3 Value-added Medicines (VAM) Development Service Market Challenges
2.3.4 Value-added Medicines (VAM) Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Development Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Development Service Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Development Service Market Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service Market Drivers
2.3.3 Value-added Medicines (VAM) Development Service Market Challenges
2.3.4 Value-added Medicines (VAM) Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Development Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Value-added Medicines (VAM) Development Service Market Share by Region (2020-2025)
Table 10. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Value-added Medicines (VAM) Development Service Market Share by Region (2026-2031)
Table 12. Value-added Medicines (VAM) Development Service Market Trends
Table 13. Value-added Medicines (VAM) Development Service Market Drivers
Table 14. Value-added Medicines (VAM) Development Service Market Challenges
Table 15. Value-added Medicines (VAM) Development Service Market Restraints
Table 16. Global Value-added Medicines (VAM) Development Service Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Value-added Medicines (VAM) Development Service Market Share by Players (2020-2025)
Table 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
Table 19. Ranking of Global Top Value-added Medicines (VAM) Development Service Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Development Service Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Value-added Medicines (VAM) Development Service, Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
Table 23. Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Development Service Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2020-2025)
Table 27. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2026-2031)
Table 29. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2020-2025)
Table 31. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2026-2031)
Table 33. North America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 48. Altus Drug Development Company Details
Table 49. Altus Drug Development Business Overview
Table 50. Altus Drug Development Value-added Medicines (VAM) Development Service Product
Table 51. Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 52. Altus Drug Development Recent Development
Table 53. TIEFENBACHER GROUP Company Details
Table 54. TIEFENBACHER GROUP Business Overview
Table 55. TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Product
Table 56. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 57. TIEFENBACHER GROUP Recent Development
Table 58. Hyloris Pharmaceuticals SA Company Details
Table 59. Hyloris Pharmaceuticals SA Business Overview
Table 60. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Product
Table 61. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 62. Hyloris Pharmaceuticals SA Recent Development
Table 63. Adamed Company Details
Table 64. Adamed Business Overview
Table 65. Adamed Value-added Medicines (VAM) Development Service Product
Table 66. Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 67. Adamed Recent Development
Table 68. Colonis Company Details
Table 69. Colonis Business Overview
Table 70. Colonis Value-added Medicines (VAM) Development Service Product
Table 71. Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 72. Colonis Recent Development
Table 73. Towa International Company Details
Table 74. Towa International Business Overview
Table 75. Towa International Value-added Medicines (VAM) Development Service Product
Table 76. Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 77. Towa International Recent Development
Table 78. Galenicap Company Details
Table 79. Galenicap Business Overview
Table 80. Galenicap Value-added Medicines (VAM) Development Service Product
Table 81. Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 82. Galenicap Recent Development
Table 83. Sandoz AG Company Details
Table 84. Sandoz AG Business Overview
Table 85. Sandoz AG Value-added Medicines (VAM) Development Service Product
Table 86. Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 87. Sandoz AG Recent Development
Table 88. Adragos Pharma Company Details
Table 89. Adragos Pharma Business Overview
Table 90. Adragos Pharma Value-added Medicines (VAM) Development Service Product
Table 91. Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 92. Adragos Pharma Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Development Service Picture
Figure 2. Global Value-added Medicines (VAM) Development Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Value-added Medicines (VAM) Development Service Market Share by Type: 2024 VS 2031
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Value-added Medicines (VAM) Development Service Market Share by Application: 2024 VS 2031
Figure 10. Pharmaceutical Companies Case Studies
Figure 11. Biotech Companies Case Studies
Figure 12. Hospitals and Medical Institutions Case Studies
Figure 13. Value-added Medicines (VAM) Development Service Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Development Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Value-added Medicines (VAM) Development Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Value-added Medicines (VAM) Development Service Market Share by Region: 2024 VS 2031
Figure 17. Global Value-added Medicines (VAM) Development Service Market Share by Players in 2024
Figure 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Development Service Revenue in 2024
Figure 20. North America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 22. United States Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 26. Germany Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Value-added Medicines (VAM) Development Service Market Share by Region (2020-2031)
Figure 34. China Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 42. Mexico Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 46. Turkey Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Altus Drug Development Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 50. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 51. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 52. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 53. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 54. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 55. Galenicap Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 56. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 57. Adragos Pharma Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Development Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Value-added Medicines (VAM) Development Service Market Share by Region (2020-2025)
Table 10. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Value-added Medicines (VAM) Development Service Market Share by Region (2026-2031)
Table 12. Value-added Medicines (VAM) Development Service Market Trends
Table 13. Value-added Medicines (VAM) Development Service Market Drivers
Table 14. Value-added Medicines (VAM) Development Service Market Challenges
Table 15. Value-added Medicines (VAM) Development Service Market Restraints
Table 16. Global Value-added Medicines (VAM) Development Service Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Value-added Medicines (VAM) Development Service Market Share by Players (2020-2025)
Table 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
Table 19. Ranking of Global Top Value-added Medicines (VAM) Development Service Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Development Service Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Value-added Medicines (VAM) Development Service, Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
Table 23. Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Development Service Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2020-2025)
Table 27. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2026-2031)
Table 29. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2020-2025)
Table 31. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2026-2031)
Table 33. North America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
Table 48. Altus Drug Development Company Details
Table 49. Altus Drug Development Business Overview
Table 50. Altus Drug Development Value-added Medicines (VAM) Development Service Product
Table 51. Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 52. Altus Drug Development Recent Development
Table 53. TIEFENBACHER GROUP Company Details
Table 54. TIEFENBACHER GROUP Business Overview
Table 55. TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Product
Table 56. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 57. TIEFENBACHER GROUP Recent Development
Table 58. Hyloris Pharmaceuticals SA Company Details
Table 59. Hyloris Pharmaceuticals SA Business Overview
Table 60. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Product
Table 61. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 62. Hyloris Pharmaceuticals SA Recent Development
Table 63. Adamed Company Details
Table 64. Adamed Business Overview
Table 65. Adamed Value-added Medicines (VAM) Development Service Product
Table 66. Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 67. Adamed Recent Development
Table 68. Colonis Company Details
Table 69. Colonis Business Overview
Table 70. Colonis Value-added Medicines (VAM) Development Service Product
Table 71. Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 72. Colonis Recent Development
Table 73. Towa International Company Details
Table 74. Towa International Business Overview
Table 75. Towa International Value-added Medicines (VAM) Development Service Product
Table 76. Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 77. Towa International Recent Development
Table 78. Galenicap Company Details
Table 79. Galenicap Business Overview
Table 80. Galenicap Value-added Medicines (VAM) Development Service Product
Table 81. Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 82. Galenicap Recent Development
Table 83. Sandoz AG Company Details
Table 84. Sandoz AG Business Overview
Table 85. Sandoz AG Value-added Medicines (VAM) Development Service Product
Table 86. Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 87. Sandoz AG Recent Development
Table 88. Adragos Pharma Company Details
Table 89. Adragos Pharma Business Overview
Table 90. Adragos Pharma Value-added Medicines (VAM) Development Service Product
Table 91. Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
Table 92. Adragos Pharma Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Development Service Picture
Figure 2. Global Value-added Medicines (VAM) Development Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Value-added Medicines (VAM) Development Service Market Share by Type: 2024 VS 2031
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Value-added Medicines (VAM) Development Service Market Share by Application: 2024 VS 2031
Figure 10. Pharmaceutical Companies Case Studies
Figure 11. Biotech Companies Case Studies
Figure 12. Hospitals and Medical Institutions Case Studies
Figure 13. Value-added Medicines (VAM) Development Service Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Development Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Value-added Medicines (VAM) Development Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Value-added Medicines (VAM) Development Service Market Share by Region: 2024 VS 2031
Figure 17. Global Value-added Medicines (VAM) Development Service Market Share by Players in 2024
Figure 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Development Service Revenue in 2024
Figure 20. North America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 22. United States Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 26. Germany Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Value-added Medicines (VAM) Development Service Market Share by Region (2020-2031)
Figure 34. China Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 42. Mexico Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
Figure 46. Turkey Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Altus Drug Development Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 50. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 51. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 52. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 53. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 54. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 55. Galenicap Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 56. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 57. Adragos Pharma Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232